Pavlo Kot

Tyra Biosciences initiates Phase 2 SURF302 trial for oral FGFR3-selective inhibitor in NMIBC

Tyra Biosciences initiates Phase 2 SURF302 trial for oral FGFR3-selective inhibitor in NMIBC
Tyra launches Phase 2 NMIBC trial

Tyra Biosciences has begun its Phase 2 SURF302 study, investigating an oral FGFR3-selective inhibitor as a potential treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

The company aims to expand treatment options for this patient group, which often faces recurring disease and requires ongoing monitoring and procedures. The announcement reflects Tyra Biosciences's focus on advancing innovative therapies for bladder cancer.

Tyra Biosciences previously published a study in the Journal of Medicinal Chemistry on FGFR3-selective inhibitors for urologic cancers, including research on their approach to drug development. Details of this research were covered in a recent company update. The study highlights the company's ongoing work in targeted cancer therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.